ERBB2 and cancer: A cost-effectiveness analysis based on the ToGA trial showed that the ICER per year-of-life gained was EUR 81 thousand in all HER2+ cancer patients, while it decreased to EUR 60 thousand and EUR 39 thousand in specific HER2 patient subgroups [17].